TAK (Takeda Pharmaceutical Co) Cyclically Adjusted Revenue per Share: $8.26 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TAK Takeda Pharmaceutical Co Ltd TAK
76 GF Score
Price $17.09
GF Value $14.10
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Takeda Pharmaceutical Co TAK -0.93% 76 Cyclically Adjusted Revenue per Share is $8.26 as of Jun. 2026. GuruFocus rates TAK with a GF Score™ of 76/100 and a GF Value™ of $14.10 (Modestly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Takeda Pharmaceutical Co's adjusted revenue per share for the three months ended in Jun. 2026 was $2.364. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $8.26 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Takeda Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 2.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Takeda Pharmaceutical Co was 4.70% per year. The lowest was 1.10% per year. And the median was 2.50% per year.

As of today (2026-08-02), Takeda Pharmaceutical Co's current stock price is $17.09. Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $8.26. Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.07.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Takeda Pharmaceutical Co was 3.13. The lowest was 1.34. And the median was 1.79.


Takeda Pharmaceutical Co  (NYSE:TAK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=17.09/8.26
=2.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Takeda Pharmaceutical Co was 3.13. The lowest was 1.34. And the median was 1.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.16 8.91 8.12 8.65 8.58

Takeda Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.04 8.81 8.46 8.58 8.26

TAK vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TAK
76GF Score
Takeda Pharmaceutical Co Ltd TAK
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Takeda Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.364/113.6000*113.6000
=2.364

Current CPI (Jun. 2026) = 113.6000.

Takeda Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.613 98.000 3.029
201612 2.555 98.400 2.950
201703 2.338 98.100 2.707
201706 2.573 98.500 2.967
201709 2.488 98.800 2.861
201712 2.748 99.400 3.141
201803 2.396 99.200 2.744
201806 2.598 99.200 2.975
201809 2.439 99.900 2.773
201812 2.823 99.700 3.217
201903 2.075 99.700 2.364
201906 2.517 99.800 2.865
201909 2.414 100.100 2.740
201912 2.528 100.500 2.858
202003 2.278 100.300 2.580
202006 2.380 99.900 2.706
202009 2.375 99.900 2.701
202012 2.558 99.300 2.926
202103 2.250 99.900 2.559
202106 2.774 99.500 3.167
202109 2.426 100.100 2.753
202112 2.514 100.100 2.853
202203 2.337 101.100 2.626
202206 2.335 101.800 2.606
202209 2.237 103.100 2.465
202212 2.588 104.100 2.824
202303 2.258 104.400 2.457
202306 2.393 105.200 2.584
202309 2.254 106.200 2.411
202312 2.390 106.800 2.542
202403 2.212 107.200 2.344
202406 2.408 108.200 2.528
202409 2.556 108.900 2.666
202412 2.310 110.700 2.371
202503 2.191 111.100 2.240
202506 2.411 111.700 2.452
202509 2.346 112.000 2.380
202512 2.381 113.000 2.394
202603 2.184 112.700 2.201
202606 2.364 113.600 2.364

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $8.26 mean?
Takeda Pharmaceutical Co (TAK) has a Cyclically Adjusted Revenue per Share of $8.26 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Takeda Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is $8.26. Overall, Takeda Pharmaceutical Co has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share of $8.26 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is $8.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TAK) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.10, compared to a current price of $17.09 — trading 21.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $8.26. Takeda Pharmaceutical Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TAK), the current Cyclically Adjusted Revenue per Share is $8.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (TAK) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of $17.09 is trading 21.2% above its estimated GF Value™ of $14.10. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for TAK:

  • Cyclically Adjusted Revenue per Share: $8.26
  • GF Value™: $14.10 vs. price of $17.09 (21.2% above fair value)
  • GF Score™: 76/100 with 10 warning signs

No single metric tells the full story. See the TAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
76GF Score

Get the complete analysis for TAK

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.09
Price
$14.10
GF Value